191 related articles for article (PubMed ID: 16167284)
1. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
[TBL] [Abstract][Full Text] [Related]
2. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; International Tobrex X Group Eu G; Stroman D; Cupp G; Martinez C; Tirado M; Guasch J
Eur J Ophthalmol; 2005 Sep - Oct 2005; 15(5):541-549. PubMed ID: 28221457
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Protzko E; Bowman L; Abelson M; Shapiro A;
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
6. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
8. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
9. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
[TBL] [Abstract][Full Text] [Related]
11. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
15. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.
Jackson WB; Low DE; Dattani D; Whitsitt PF; Leeder RG; MacDougall R
Can J Ophthalmol; 2002 Jun; 37(4):228-37; discussion 237. PubMed ID: 12095096
[TBL] [Abstract][Full Text] [Related]
17. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.
Cochereau I; Meddeb-Ouertani A; Khairallah M; Amraoui A; Zaghloul K; Pop M; Delval L; Pouliquen P; Tandon R; Garg P; Goldschmidt P; Bourcier T
Br J Ophthalmol; 2007 Apr; 91(4):465-9. PubMed ID: 17050578
[TBL] [Abstract][Full Text] [Related]
18. A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.
Yee RW; Tepedino M; Bernstein P; Jensen H; Schiffman R; Whitcup SM;
Curr Med Res Opin; 2005 Mar; 21(3):425-31. PubMed ID: 15811211
[TBL] [Abstract][Full Text] [Related]
19. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
Tepedino ME; Heller WH; Usner DW; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL
Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
